272 related articles for article (PubMed ID: 28754670)
1. Gemcitabine and Chk1 Inhibitor AZD7762 Synergistically Suppress the Growth of Lkb1-Deficient Lung Adenocarcinoma.
Liu Y; Li Y; Wang X; Liu F; Gao P; Quinn MM; Li F; Merlino AA; Benes C; Liu Q; Gray NS; Wong KK
Cancer Res; 2017 Sep; 77(18):5068-5076. PubMed ID: 28754670
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of radiosensitization by the Chk1/2 inhibitor AZD7762 involves abrogation of the G2 checkpoint and inhibition of homologous recombinational DNA repair.
Morgan MA; Parsels LA; Zhao L; Parsels JD; Davis MA; Hassan MC; Arumugarajah S; Hylander-Gans L; Morosini D; Simeone DM; Canman CE; Normolle DP; Zabludoff SD; Maybaum J; Lawrence TS
Cancer Res; 2010 Jun; 70(12):4972-81. PubMed ID: 20501833
[TBL] [Abstract][Full Text] [Related]
3. Checkpoint kinase inhibitor AZD7762 strongly sensitises urothelial carcinoma cells to gemcitabine.
Isono M; Hoffmann MJ; Pinkerneil M; Sato A; Michaelis M; Cinatl J; Niegisch G; Schulz WA
J Exp Clin Cancer Res; 2017 Jan; 36(1):1. PubMed ID: 28049532
[TBL] [Abstract][Full Text] [Related]
4. Checkpoint kinase inhibitor synergizes with DNA-damaging agents in G1 checkpoint-defective neuroblastoma.
Xu H; Cheung IY; Wei XX; Tran H; Gao X; Cheung NK
Int J Cancer; 2011 Oct; 129(8):1953-62. PubMed ID: 21154747
[TBL] [Abstract][Full Text] [Related]
5. Checkpoint kinase 1 protein expression indicates sensitization to therapy by checkpoint kinase 1 inhibition in non-small cell lung cancer.
Grabauskiene S; Bergeron EJ; Chen G; Thomas DG; Giordano TJ; Beer DG; Morgan MA; Reddy RM
J Surg Res; 2014 Mar; 187(1):6-13. PubMed ID: 24418519
[TBL] [Abstract][Full Text] [Related]
6. Assessment of chk1 phosphorylation as a pharmacodynamic biomarker of chk1 inhibition.
Parsels LA; Qian Y; Tanska DM; Gross M; Zhao L; Hassan MC; Arumugarajah S; Parsels JD; Hylander-Gans L; Simeone DM; Morosini D; Brown JL; Zabludoff SD; Maybaum J; Lawrence TS; Morgan MA
Clin Cancer Res; 2011 Jun; 17(11):3706-15. PubMed ID: 21482692
[TBL] [Abstract][Full Text] [Related]
7. Role of CPS1 in Cell Growth, Metabolism and Prognosis in LKB1-Inactivated Lung Adenocarcinoma.
Çeliktas M; Tanaka I; Tripathi SC; Fahrmann JF; Aguilar-Bonavides C; Villalobos P; Delgado O; Dhillon D; Dennison JB; Ostrin EJ; Wang H; Behrens C; Do KA; Gazdar AF; Hanash SM; Taguchi A
J Natl Cancer Inst; 2017 Mar; 109(3):1-9. PubMed ID: 28376202
[TBL] [Abstract][Full Text] [Related]
8. AZD7762, a novel checkpoint kinase inhibitor, drives checkpoint abrogation and potentiates DNA-targeted therapies.
Zabludoff SD; Deng C; Grondine MR; Sheehy AM; Ashwell S; Caleb BL; Green S; Haye HR; Horn CL; Janetka JW; Liu D; Mouchet E; Ready S; Rosenthal JL; Queva C; Schwartz GK; Taylor KJ; Tse AN; Walker GE; White AM
Mol Cancer Ther; 2008 Sep; 7(9):2955-66. PubMed ID: 18790776
[TBL] [Abstract][Full Text] [Related]
9. WEE1 Kinase Inhibitor AZD1775 Has Preclinical Efficacy in LKB1-Deficient Non-Small Cell Lung Cancer.
Richer AL; Cala JM; O'Brien K; Carson VM; Inge LJ; Whitsett TG
Cancer Res; 2017 Sep; 77(17):4663-4672. PubMed ID: 28652249
[TBL] [Abstract][Full Text] [Related]
10. The clinical development candidate CCT245737 is an orally active CHK1 inhibitor with preclinical activity in RAS mutant NSCLC and Eµ-MYC driven B-cell lymphoma.
Walton MI; Eve PD; Hayes A; Henley AT; Valenti MR; De Haven Brandon AK; Box G; Boxall KJ; Tall M; Swales K; Matthews TP; McHardy T; Lainchbury M; Osborne J; Hunter JE; Perkins ND; Aherne GW; Reader JC; Raynaud FI; Eccles SA; Collins I; Garrett MD
Oncotarget; 2016 Jan; 7(3):2329-42. PubMed ID: 26295308
[TBL] [Abstract][Full Text] [Related]
11. LKB1 and KEAP1/NRF2 Pathways Cooperatively Promote Metabolic Reprogramming with Enhanced Glutamine Dependence in
Galan-Cobo A; Sitthideatphaiboon P; Qu X; Poteete A; Pisegna MA; Tong P; Chen PH; Boroughs LK; Rodriguez MLM; Zhang W; Parlati F; Wang J; Gandhi V; Skoulidis F; DeBerardinis RJ; Minna JD; Heymach JV
Cancer Res; 2019 Jul; 79(13):3251-3267. PubMed ID: 31040157
[TBL] [Abstract][Full Text] [Related]
12. Dissociation of gemcitabine chemosensitization by CHK1 inhibition from cell cycle checkpoint abrogation and aberrant mitotic entry.
Parsels LA; Tanska DM; Parsels JD; Zabludoff SD; Cuneo KC; Lawrence TS; Maybaum J; Morgan MA
Cell Cycle; 2016; 15(5):730-9. PubMed ID: 26890478
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of acetyl-CoA carboxylase suppresses fatty acid synthesis and tumor growth of non-small-cell lung cancer in preclinical models.
Svensson RU; Parker SJ; Eichner LJ; Kolar MJ; Wallace M; Brun SN; Lombardo PS; Van Nostrand JL; Hutchins A; Vera L; Gerken L; Greenwood J; Bhat S; Harriman G; Westlin WF; Harwood HJ; Saghatelian A; Kapeller R; Metallo CM; Shaw RJ
Nat Med; 2016 Oct; 22(10):1108-1119. PubMed ID: 27643638
[TBL] [Abstract][Full Text] [Related]
14. Chk1 inhibition after replicative stress activates a double strand break response mediated by ATM and DNA-dependent protein kinase.
McNeely S; Conti C; Sheikh T; Patel H; Zabludoff S; Pommier Y; Schwartz G; Tse A
Cell Cycle; 2010 Mar; 9(5):995-1004. PubMed ID: 20160494
[TBL] [Abstract][Full Text] [Related]
15. Combined CDKN1A/TP53 mutation in bladder cancer is a therapeutic target.
Liu Y; Kwiatkowski DJ
Mol Cancer Ther; 2015 Jan; 14(1):174-82. PubMed ID: 25349305
[TBL] [Abstract][Full Text] [Related]
16. YAP promotes malignant progression of Lkb1-deficient lung adenocarcinoma through downstream regulation of survivin.
Zhang W; Gao Y; Li F; Tong X; Ren Y; Han X; Yao S; Long F; Yang Z; Fan H; Zhang L; Ji H
Cancer Res; 2015 Nov; 75(21):4450-7. PubMed ID: 26363011
[TBL] [Abstract][Full Text] [Related]
17. The hexosamine biosynthesis pathway is a targetable liability in KRAS/LKB1 mutant lung cancer.
Kim J; Lee HM; Cai F; Ko B; Yang C; Lieu EL; Muhammad N; Rhyne S; Li K; Haloul M; Gu W; Faubert B; Kaushik AK; Cai L; Kasiri S; Marriam U; Nham K; Girard L; Wang H; Sun X; Kim J; Minna JD; Unsal-Kacmaz K; DeBerardinis RJ
Nat Metab; 2020 Dec; 2(12):1401-1412. PubMed ID: 33257855
[TBL] [Abstract][Full Text] [Related]
18. A kinome screen identifies checkpoint kinase 1 (CHK1) as a sensitizer for RRM1-dependent gemcitabine efficacy.
Zhou J; Chen Z; Malysa A; Li X; Oliveira P; Zhang Y; Bepler G
PLoS One; 2013; 8(3):e58091. PubMed ID: 23483975
[TBL] [Abstract][Full Text] [Related]
19. Chk1 inhibition as a novel therapeutic strategy for treating triple-negative breast and ovarian cancers.
Bryant C; Rawlinson R; Massey AJ
BMC Cancer; 2014 Aug; 14():570. PubMed ID: 25104095
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of autophagy and MEK promotes ferroptosis in Lkb1-deficient Kras-driven lung tumors.
Bhatt V; Lan T; Wang W; Kong J; Lopes EC; Wang J; Khayati K; Raju A; Rangel M; Lopez E; Hu ZS; Luo X; Su X; Malhotra J; Hu W; Pine SR; White E; Guo JY
Cell Death Dis; 2023 Jan; 14(1):61. PubMed ID: 36702816
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]